Biotechnology · DeepTech · Health · Manufacturing
1 - 10 employees
CAR-T therapy is a form of cancer treatment that uses a chimeric antigen receptor (CAR) to target killer T-cells towards tumour cells in the body. The first marketed CAR-T therapies, Kymriah and Yescarta, have been able to cure over 60% of previously hopeless leukaemia cases. However, the method currently requires therapeutic cells to be modified and grown outside the body, which is a highly complex and expensive process. The production process results in cells of variable quality, and treatments priced in the £100,000s. In addition, these therapies currently only work well in blood cancers (less than 4% of total cases), and more effective cell products are needed to make an impact on other tumours. ImmTune Therapies is designing vectors that can deliver the CARs directly to T-cells inside the body. This will allow the body itself to develop these therapeutic cells; a process we expect to be considerably cheaper, and to produce more effective products. This will allow ImmTune to platform and empower the revolutionary cancer medicines of tomorrow.Something looks off?